Aura Biosciences Q1 net loss widens to $33.7 million

• Aura Biosciences posted a net loss of USD 33.7 million, widening from USD 27.5 million a year earlier; loss per share narrowed to USD 0.5 from USD 0.55.
• Research and development costs climbed 20% to USD 28 million, general and administrative expense rose to USD 6.9 million from USD 5.7 million.
• Cash, cash equivalents, marketable securities totaled USD 114.7 million at March 31; received USD 280.8 million in net proceeds from a May public offering, using about USD 39 million for a stock repurchase.
• Phase 3 CoMpass trial of bel-sar in early choroidal melanoma advanced toward enrollment completion expected by mid-2026, with topline data for the 15-month primary endpoint slated for 2H 2027.
• Natalie Holles said Aura is entering a pivotal period as it advances CoMpass toward potential registration; cash runway expected to extend into 2H 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aura Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605111601PRIMZONEFULLFEED9716671) on May 11, 2026, and is solely responsible for the information contained therein.